

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/435, 16/00, G01N 33/569, A61K 39/00	A1	(11) International Publication Number: WO 00/50450	
		(43) International Publication Date: 31 August 2000 (31.08.00)	
(21) International Application Number: PCT/SE00/00346	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), European patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Eurasian patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).		
(22) International Filing Date: 22 February 2000 (22.02.00)			
(30) Priority Data: 9900674-4 25 February 1999 (25.02.99) SE			
(71) Applicant (for all designated States except US): STATENS VETERINÄRMEDICINSKA ANSTALT [SE/SE]; S-751 89 Uppsala (SE)	Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>		
(72) Inventor; and (75) Inventor/Applicant (for US only): MATTISSON, Jens [SE/SE]; Odlingstigen 2A, S-756 55 Uppsala (SE).			
(74) Agents: BERG, S., A. et al.; Albilnas Patentbyrå Stockholm AB, P.O. Box 5381, S-114 85 Stockholm (SE).			

(54) Title: MITE PROTEIN

(57) Abstract

The present invention relates to a novel major mite antigen, which according to the invention has been isolated and sequenced for the first time. More specifically, said antigen is a protein originating from the mite *Sarcoptes scabiei*. Thus, the invention relates to said antigen as well as to the encoding nucleic acid as defined in the claims. Further, the invention also relates to advantageous uses of the novel protein and/or functional fragments thereof, e.g. in immunological testing, such as in ELISA methods, as well as in the preparation of vaccines.